Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 9/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27258266 | 0.69 | IDO1 (0.60) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL7194641 | 0.64 | IDO1 (0.59) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL725527 | 0.64 | CYP3A4 (0.48) | IDO1CYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL2358975 | 0.62 | HPGDS (1.00) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL2593988 | 0.62 | IDO1 (0.42) | IDO1CYP3A4CYP2D6CYP2E1CYP2A6 | |
| SCHEMBL191327 | 0.61 | — | — | |
| SCHEMBL27880327 | 0.60 | IDO1 (0.67) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL17800997 | 0.60 | IDO1 (0.75) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL28750838 | 0.58 | ASIC3 (0.53) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 | |
| SCHEMBL26265591 | 0.58 | CYP11B1 (0.85) | HPGDSIDO1CYP3A4CYP2D6CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7858637-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | AVERETT DEVRON R | 2010-12-28 | — | — | US | disclosed |
| US-20100256169-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1667694-B1 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7576068-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ANADYS PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| EP-1758916-A1 | 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | Anadys Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1667694-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | Anadys Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005121162-A1 | 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050182001-A1 | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-20030199461-A1 | 3-beta-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | HPGDS 2157/4885IDO1 1947/4885CYP3A4 390/4885 |
| US-20030199461-A1 | 3-beta-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof | DPYD, TYMP, ENTPD5 | HPGDS 363/4885IDO1 88/4885CYP3A4 2884/4885 |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | HPGDS 2157/4885IDO1 1947/4885CYP3A4 390/4885 |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ADORA2B, DPYD, ADAR | HPGDS 844/4885IDO1 331/4885CYP3A4 2412/4885 |
| US-20100256169-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | HPGDS 2157/4885IDO1 1947/4885CYP3A4 390/4885 |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | TLR7, TLR3, TLR9 | HPGDS 2157/4885IDO1 1947/4885CYP3A4 390/4885 |
| US-20050182001-A1 | 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof | TYMP, DPYD, ENTPD5 | HPGDS 317/4885IDO1 165/4885CYP3A4 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.